GSK,SNY -

. Currency in USD
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Sanofi Wants to Go It Alone -- Good Luck With That
    Bloomberg6 hours ago

    Sanofi Wants to Go It Alone -- Good Luck With That

    The French drugmaker's in-house R&D efforts have been unimpressive.

  • Lilly Issues Guidance for 2018, New Drugs to Drive Top Line
    Zacks10 hours ago

    Lilly Issues Guidance for 2018, New Drugs to Drive Top Line

    Eli Lilly (LLY) issues financial guidance for 2018 and also reaffirms the previously issued 2017 projection as well as its long-term expectations.

  • 10 Biggest Antidepressant Drug Companies In 2017
    Insider Monkey10 hours ago

    10 Biggest Antidepressant Drug Companies In 2017

    The 10 biggest antidepressant drug companies in 2017 are committed to providing the safest and most cost-effective solution for consumers suffering from mental diseases worldwide. According to Journal of the American Medical Association, one out of six Americans consumes psychiatric medicine and about 12% of these drugs are antidepressants. Depression is a state of mind, […]

  • Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
    Motley Fool23 hours ago

    Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?

    An immuno-oncology drug that's in the works could generate significant revenue growth someday.

  • Regeneron, Sanofi Report Positive Top Line Skin Cancer Data
    Zacksyesterday

    Regeneron, Sanofi Report Positive Top Line Skin Cancer Data

    Regeneron (REGN) and partner Sanofi announced positive top-line results from a pivotal phase II study of skin cancer candidate cemiplimab.

  • Benzingayesterday

    ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More

    The curtains have come down on one of the most-watched annual biotech conferences. The 59th annual meeting of the American Society of Hematology was held Dec. 9-12 in Atlanta.  This year's meeting was ...

  • Top 10 Generic Pharmaceutical Companies In 2017
    Insider Monkeyyesterday

    Top 10 Generic Pharmaceutical Companies In 2017

    The top 10 generic pharmaceutical companies in 2017 operate in the relatively recession-proof pharmaceuticals industry which is immune from the vagaries of economic cycles. The huge R&D expense and expertise required to develop new medicines is a big entry barrier and the patent laws allow pharmaceuticals companies to make monopolistic profits for a new product […]

  • Reutersyesterday

    France's Sanofi pins hopes on new drugs after setbacks

    Sanofi's (SASY.PA) promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and concerns about a dengue vaccine, the French pharmaceuticals group said on Wednesday. The world's sixth largest drugmaker, battling to contain the fallout from a safety row in the Philippines over dengue vaccine Dengvaxia, said it expected to file nine medicines for regulatory assessment in the next 18 months. Shares in Sanofi were down 0.77 percent at 1510 GMT.

  • Reutersyesterday

    France's Sanofi pins hopes on new drugs after setbacks

    Sanofi's promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and concerns about a dengue vaccine, the French pharmaceuticals group said on Wednesday. The world's sixth largest drugmaker, battling to contain the fallout from a safety row in the Philippines over dengue vaccine Dengvaxia, said it expected to file nine medicines for regulatory assessment in the next 18 months. Shares in Sanofi were down 0.77 percent at 1510 GMT.

  • Glaxo's Nucala Label Expansion Application Gets FDA Approval
    Zacksyesterday

    Glaxo's Nucala Label Expansion Application Gets FDA Approval

    GlaxoSmithKline's (GSK) application to include treatment of eosinophilic granulomatosis with polyangiitis in Nucala's label was approved by the FDA.

  • Reuters2 days ago

    Sanofi CEO says M&A targets in oncology are 'very expensive'

    PARIS (Reuters) - Sanofi's Chief Executive Olivier Brandicourt on Wednesday told investors that he considered M&A targets in oncology to be "very expensive". "If you are not starting with ...

  • Reuters2 days ago

    Did Sanofi, WHO ignore warning signals on dengue vaccine?

    CHICAGO/LONDON (Reuters) - When French drugmaker Sanofi published the results of clinical trials of children given its dengue vaccine two years ago, the overall findings were that it protected against the world's biggest and fastest growing mosquito-borne disease. The study's authors cited two main possibilities: the children had immature immune systems that made the vaccine less protective, or the vaccine itself made them more susceptible to severe disease if they had never had dengue and later became infected. More than two years later, it turns out the latter was the primary factor - a revelation at the end of last month that has triggered alarm among hundreds of thousands of anxious parents in the Philippines, where the vaccine has been given to over 830,000 children.

  • Reuters2 days ago

    Did Sanofi, WHO ignore warning signals on dengue vaccine?

    CHICAGO/LONDON, Dec 12 (Reuters) - When French drugmaker Sanofi published the results of clinical trials of children given its dengue vaccine two years ago, the overall findings were that it protected against the world's biggest and fastest growing mosquito-borne disease. The study's authors cited two main possibilities: the children had immature immune systems that made the vaccine less protective, or the vaccine itself made them more susceptible to severe disease if they had never had dengue and later became infected. More than two years later, it turns out the latter was the primary factor - a revelation at the end of last month that has triggered alarm among hundreds of thousands of anxious parents in the Philippines, where the vaccine has been given to over 830,000 children.

  • TheStreet.com2 days ago

    Dengue Fever Vaccine Suspension Criticized by Drugmaker Sanofi

    French drug-maker Sanofi contends its Dengue vaccine is good for the country. After 730,000 children were vaccinated, the Philippine government stopped the program on data the drug-maker released that ...

  • Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog
    Zacks2 days ago

    Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog

    Sanofi's (SNY) Admelog, a follow-on biologic version of Lilly's Humalog, received FDA approval.

  • Reuters3 days ago

    Sanofi investors hungry for drug progress and deal news

    Sanofi (SASY.PA) still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters. The French drugmaker holds an "innovation day" on Wednesday to discuss its pipeline of new drugs while it attempts to overcome fallout from a safety row in the Philippines over its dengue vaccine. Shares in Sanofi are trading close to a 10-month low and are down more than 4 percent this year after a 2.2 percent decline last year.

  • Reuters3 days ago

    Sanofi investors hungry for drug progress and deal news

    Sanofi still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters. The French drugmaker holds an "innovation day" on Wednesday to discuss its pipeline of new drugs while it attempts to overcome fallout from a safety row in the Philippines over its dengue vaccine. Shares in Sanofi are trading close to a 10-month low and are down more than 4 percent this year after a 2.2 percent decline last year.

  • Reuters3 days ago

    FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. Admelog, generally taken just before meals, was approved for use in children older than three and adults with type 1 diabetes, as well as adults with type 2 diabetes. Like Humalog, which earned Lilly $696.2 million in the latest quarter, the short-acting drug helps diabetics control blood sugar levels after eating.

  • Reuters3 days ago

    FDA clears Sanofi's follow-on diabetes biologic of Lilly's Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. The drug is a short-acting ...

  • 3 High-Yield Dividend Stocks to Buy in 2018
    Motley Fool3 days ago

    3 High-Yield Dividend Stocks to Buy in 2018

    These 3 Big Pharma stocks may be worth adding to your portfolio in 2018.

  • Glaxo's New Pharma Head Looks to Move Fast, Especially in Cancer
    Bloomberg4 days ago

    Glaxo's New Pharma Head Looks to Move Fast, Especially in Cancer

    GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, signaled it will look to speed development of an experimental cancer treatment as part of its ambition to expand in oncology just two years after selling ...

  • Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound?
    Zacks4 days ago

    Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound?

    Regeneron (REGN) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Capital Cube6 days ago

    ETFs with exposure to GlaxoSmithKline Plc : December 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to GlaxoSmithKline Plc Here are 5 ETFs with the largest exposure to GSK-US. Comparing the performance and risk of GlaxoSmithKline Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • American City Business Journals6 days ago

    GlaxoSmithKline's Rockville chief lays out priorities for 2018

    British pharmaceutical giant GlaxoSmithKline PLC said it finally has a full team in place at its vaccine hub in Rockville and is ready to take on some of the region's most well-known biotech competitors with part of its product lineup. This next year, officials said, will be about taking a leadership position in new vaccine technologies and advancing its priority projects, including a vaccine for shingles as well its vaccine candidate for respiratory syncytial virus, a common respiratory virus that often attacks infants and the elderly — and a key disease target already for major players such as MedImmune and Novavax Inc. "It's really getting down to business and doing the work," said Rip Ballou, vice president and head of GSK's (GSK) Global Vaccines U.S. Research and Development Center in Rockville.

  • Sanofi Begins Combo Studies on Multiple Myeloma Candidate
    Zacks6 days ago

    Sanofi Begins Combo Studies on Multiple Myeloma Candidate

    Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.